SGHT

In May 2026, the company reported its first-quarter 2026 financial results, showing a 13% increase in total revenue year-over-year and a 244% increase in Interventional Dry Eye revenue, leading to raised full-year 2026 revenue guidance. Additionally, a U.S. District Court issued a final judgment in a patent infringement case against Alcon, awarding Sight Sciences $55.4 million in past monetary damages and an ongoing 10% royalty on Hydrus® Microstent revenue. In August 2026, Sight Sciences announced FDA 510(k) clearance of the OMNI® Ultra Surgical System and reported strong second-quarter 2026 financial results, with total revenue up 20% year-over-year and Interventional Dry Eye revenue increasing by 704%, again raising full-year 2026 revenue guidance and reducing adjusted operating expense guidance. During this period, Aetna, Humana, and Highmark expanded coverage for OMNI, SION, and TearCare systems, adding millions of insured lives, and the FDA updated the TearCare® System's Indications for Use, making it the first and only MGD treatment indicated to improve meibomian gland function. In September 2026, Sight Sciences presented at the Morgan Stanley Global Healthcare Conference. In October 2026, the company is set to debut the OMNI Ultra® Surgical System at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting, and there were reports of an EVP selling shares to cover stock-vesting taxes, alongside insider selling by various individuals between April and July 2026.